OIS@ASRS 2016 On-Demand
OIS@ASRS 2016 On-Demand
Welcome & Retinal Innovation Highlights
Emmett T. Cunningham Jr., MD, PhD, MPH, Partner – Clarus
Retina Company Showcase
Moderated By:
Tracy Saxton, PhD, Investment Director – Roche Venture Fund
Alimera Sciences
Alimera Sciences (NASDAQ:ALIM) is located in Atlanta, Ga. Founded in June 2003, Alimera is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not optimally treated with current therapies and will affect millions of people in our aging populations. Alimera’s lead product, ILUVIEN, is a continuous microdosing system engineered to deliver fluocinolone acetonide for up to 36 months for the treatment of DME and is currently marketed in the US, UK, Germany, and Portugal.
Catalyst Biosciences
Catalyst developed proprietary technologies to create engineered human proteases with novel activities and specificities as potential therapeutic agents in ophthalmology (e.g., dry AMD) and hemophilia. Due to their catalytic mechanism of action, these drug candidates are expected to display significant differentiation versus traditional stoichiometric drugs like antibodies or small molecules.
Aerie Pharmaceuticals
Aerie is a clinical-stage pharmaceutical company focused on discovery, development and commercialization of first-in-class therapies for patients with glaucoma and other diseases of the eye. Aerie’s two lead products, RhopressaTM and RoclatanTM, are once daiIy IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma and ocular hypertension.
Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases of the eye using its proprietary hydrogel platform technology. The Company’s lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain, and allergic conjunctivitis, and Phase 2 for glaucoma and inflammatory dry eye disease. The Company is also evaluating sustained-release anti-VEGF depots. Ocular Therapeutix’s first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.
Graybug Vision
Graybug Vision is developing products for the treatment of neovascular (wet) AMD and glaucoma. The lead product, GB-102, may be dosed twice per year and contains sunitinib, a dual inhibitor of VEGF and PDGF receptors. We are also developing a twice per year subconjunctival administered product for glaucoma and neuroprotection.
Apellis Pharmaceuticals
Apellis is a clinical stage biopharmaceutical company focused on therapeutics for autoimmune and inflammatory diseases. Our lead product candidates are C3 complement inhibitors, and we have clinical programs in rare diseases (PNH), ophthalmology (geographic atrophy) and respiratory indications (COPD and IPF).
Translatum Medicus inc (TMi)
Translatum Medicus inc (TMi) is a preclinical drug development company with a lead candidate, TMi-018, for the treatment of dry Age Related Macular Degeneration. TMi-018 is a patented immunomodulatory compound that alters macrophage behaviour in a model of Geographic Atrophy prevention and expansion. TMi is a charter member of JLABS@Toronto.
Bioptigen
Bioptigen was founded in 2004 as a spin out of Duke University to commercialize advances in spectral domain OCT. In its 12 year history, Bioptigen has been recognized as an innovation leader in OCT applied to translational research and pediatric ophthalmology. Bioptigen is now a Leica Microsystems company.
TrueVision Systems
TrueVision’s Digital Microscope Platform enables a vast array of supplemental information and guidance beyond the current optical surgical microscope paradigm. TrueVision provides the surgeon superior visualization, while simultaneously integrating computer-generated guidance from multiple diagnostic measurements within the context of the live surgical view in real-time.
Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight. Bausch + Lomb is a global hallmark for innovation and quality, offering the widest and finest range of eye health products including ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments.
[/creativ_toggle]
Trends in Private Company Financing & Exits in Ophthalmology
Jonathan Norris, Managing Director – Silicon Valley Bank
Public Market Trends in Ophthalmology
Andrew Gitkin, Head, West Coast Investment Banking – Piper Jaffray
Innovation in Retinal Imaging: Opportunities & Challenges: Presentations
Introduced By:
William J. Link, PhD, Managing Director – Versant Ventures
History of Intraoperative OCT
Presented By:
Cynthia Toth, MD
[/creativ_toggle]
Innovation in Retinal Imaging: Opportunities & Challenges: Panel Discussion
Moderated By:
William J. Link, PhD, Managing Director – Versant Ventures
Participants:
Ryan Bouchard, Director, Medical Devices – Ora
Heinrich Dreyer, PhD, VP, Medical Division – Leica Microsystems
Ralf Kuschnereit, PhD, SVP Ophthalmic Systems Division – Carl Zeiss Meditec AG
Kester Nahen, PhD, Managing Director – Heidelberg Engineering
Paying for Breakthrough Eye Therapies (Biologics, Biosimilars & Gene Therapies): Company Presentations
Moderated By:
Tarek Hassan, MD
Pfenex
Pfenex Inc. (NYSE: PFNX) is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value, and difficult-to-manufacture, proteins. The Company’s lead product candidate is PF582, a biosimilar candidate to Lucentis® (ranibizumab), for the potential treatment of patients with retinal diseases.
AGTC
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC’s lead product candidates are designed to treat inherited orphan diseases of the eye.
[/creativ_toggle]
Paying for Breakthrough Eye Therapies (Biologics, Biosimilars & Gene Therapies): Panel Discussion
Co-Moderated By:
Tarek Hassan, MD
Gilbert H. Kliman, MD, Managing Director – InterWest Partners
Participants:
Jay Duker, MD
Joshua Schimmer, Senior Research Analyst – Piper Jaffray
John Thompson, MD
Trex Topping, MD
Emerging Approaches to Combination Therapies in AMD & DME: Company Presentations
Moderated By:
Mark Humayun, MD
Regeneron
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Aerpio Therapeutics
Aerpio Therapeutics is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. Our lead programs include a Tie-2 activator for diabetic macular edema (DME) and a hypoxia-inducible factor 1-α (HIF1-α) stabilizer for the treatment of inflammatory bowel disease. The lead compound for the Tie-2 program, AKB-9778, recently completed a proof-of-concept, phase 2A study (TIME-2), and the HIF1-α stabilization program is rapidly progressing toward the clinic with first-in-human trials expected to start in early 2016.
Allegro Ophthalmics
Allegro Ophthalmics is establishing integrin peptide therapy as the next-generation pharmaceutical category for the treatment of vitreoretinal diseases. Currently in multiple Phase 2 studies, Allegro’s Luminate has the potential to provide new treatment options for patients with diabetic macular edema, non-proliferative diabetic retinopathy, neovascular age-related macular degeneration and vitreomacular traction.
Opthea
Opthea (ASX:OPT) is developing OPT-302, a ‘trap’ for VEGF-C and VEGF-D that are critical mediators of blood vessel growth and leakage. Opthea is investigating OPT-302 as a monotherapy and in combination with ranibizumab in a Phase 1/2A clinical trial in wet AMD patients at 14 sites in the US.
[/creativ_toggle]
Emerging Approaches to Combination Therapies in AMD & DME: Panel Discussion
Co-Moderated By:
Emmett T. Cunningham Jr., MD, PhD, MPH, Partner – Clarus
Mark Humayun, MD
Participants:
Mark Blumenkranz, MD
Adnan Butt, Biotech Analyst – RBC Capital Markets
Donald D’Amico, MD
Pravin Dugel, MD
Peter Kaiser, MD
Masters of the Industry
Moderated By:
Jim Mazzo, Global President of Ophthalmology – Carl Zeiss Meditec
Particioants:
Tony Adamis, MD, Global Head, I2O & Metabolism, Clinical Science – Genentech
Frederic Guerard, Worldwide Business Franchise Head, Ophthalmology – Alcon
William J. Link, PhD, Managing Director – Versant Ventures
Ludwin Monz, PhD, President & CEO – Carl Zeiss Meditec AG